Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexaria Bioscience (LEXX) Depreciation and Depletion (2016 - 2022)

Historic Depreciation and Depletion for Lexaria Bioscience (LEXX) over the last 12 years, with Q2 2022 value amounting to $23893.0.

  • Lexaria Bioscience's Depreciation and Depletion fell 1445.09% to $23893.0 in Q2 2022 from the same period last year, while for May 2022 it was $105916.0, marking a year-over-year decrease of 598.87%. This contributed to the annual value of $111718.0 for FY2021, which is 91.53% down from last year.
  • According to the latest figures from Q2 2022, Lexaria Bioscience's Depreciation and Depletion is $23893.0, which was down 1445.09% from $26163.0 recorded in Q1 2022.
  • Over the past 5 years, Lexaria Bioscience's Depreciation and Depletion peaked at $28875.0 during Q3 2020, and registered a low of $462.0 during Q1 2018.
  • For the 5-year period, Lexaria Bioscience's Depreciation and Depletion averaged around $20274.2, with its median value being $26853.5 (2019).
  • Its Depreciation and Depletion has fluctuated over the past 5 years, first surged by 420094.88% in 2019, then plummeted by 1445.09% in 2022.
  • Quarter analysis of 5 years shows Lexaria Bioscience's Depreciation and Depletion stood at $1603.0 in 2018, then soared by 1616.28% to $27512.0 in 2019, then increased by 1.52% to $27929.0 in 2020, then grew by 0.0% to $27930.0 in 2021, then decreased by 14.45% to $23893.0 in 2022.
  • Its Depreciation and Depletion was $23893.0 in Q2 2022, compared to $26163.0 in Q1 2022 and $27930.0 in Q4 2021.